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ABSTRACT 
Some N-substituted-diaryl-pyrazoline analogues were investigated insilico for their docking potential towards the Cyclooxygenase 
(COX)-2 enzymes. The compounds were designed on the basis of rational selection & the PDB entry 1CX2 from RCSB Protein 
Data Bank was used for mimicking COX-2 binding sites. The Compound (E)-3-(4-(dimethylamino) phenyl)-1-(5-(4-
(dimethylamino) phenyl)-3-(4-hydroxyphenyl)-4,5 dihydropyrazol-1-yl)prop-2-en-1-one (E5) was found to possess strong binding 
potential along with two H-bond. The H-bond with Tyr-355 residue suggests desired COX-2 inhibitory potential of compound E5.       
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INTRODUCTION: 
Cyclooxygenases enzyme catalyzes formation of 
inflammatory mediators via arachidonic acid path way. 
COX-1 and COX-2 are two major isoforms of 
cyclooxygenase
1
. COX-1 considered responsible for 
platelet aggregation & gastric safety while COX-2 is 
responsible for inflammatory response
2
. Therefore, 
various COX-2 inhibitors have been developed recently 
as anti-inflammatory compounds
3
.  
Molecular docking is a computational approach used to 
investigate interactions between the ligand and 
macromolecule thus helps to predict possible drug like 
effect of ligand. Various researchers investigated 
different compounds for their insilico binding affinity 
towards COX- 1 and COX-2. The computational 
chemistry also confirms selectivity of COX inhibitors 
since ARG513 residue of COX-2 responsible for drug-
receptor binding replaced with HIS513 residue of COX-
1; therefore selective inhibitor of COX-2 does not inhibit 
COX- 1
4-5
. 
EXPERIMENTAL: 
Selection of docking parameters: 
 Torsion:        0.2 A0 
 Rigid-body orientation:      5 A0 
 Dihedral angles :       5 A0 
 Root Mean Square Deviation Tolerance:  2.0 A0  
Preparation of Ligand Structures of diaryl pyrazoline 
analogues were designed using Chem Draw 3D software 
they were further energetically minimized by MOPAC, 
with minimum RMS gradient of 0.01 and saved as MDL 
Mol File. Other parameters such as; pH, partial charges 
and polar groups were optimized using molecular 
mechanics. Rotatable bonds and types of atom were also 
optimized and assigned.   
Preparation of macromolecule (protein) 
PDB entry 1CX2 was drawn from Protein Data Bank 
and after selecting protein chain, macromolecule was 
further optimized for presence of heteroatoms and water 
molecule. Protein binding sites were selected through 
co-crystallized ligand binding interaction.   
Docking simulation Docking simulation involves 
docking of designed diaryl pyrazoline analogues with 
macromolecule (protein) after addition of hydrogen 
bonds and charge assignment. Auto-Dock online server 
was used for the same. The docking algorithm finds 
minimum energy function including interactions of the 
ligand with the receptor and optimization of best 
conformational poses. All analogues were compared 
according to the minimum free binding energy and 
formation of H-bond. 
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RESULT AND DISCUSSION:  
Designed compounds (diaryl pyrazoline analogues) were 
investigated for their binding potential with COX-2 
enzyme using docking techniques. The designed 
compounds (Figure 1) docked on the crystal structures 
of cyclooxygenase-2 available through RCSB Protein 
Data Bank (PDB entry 1CX2). The binding score of the 
compounds were calculated from minimized ligand 
protein complexes (Table 1). The score values showed 
good binding affinities and stable conformational 
complexes of ligand-receptor. The co-crystallized ligand 
Celecoxib reveals hydrogen bonds with Tyr355, His90 
and Arg513 (Figure 2), while Diarylpyrazoline 
derivative E5 showed similar hydrogen bonds with 
Tyr355 and high binding affinity (Figure 3). Other 
compounds also exhibited good binding score without 
hydrogen bond might be due to the other bonding 
interactions.  
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Figure 1: Structures of designed ligands
 
Table 1: Binding Score of Compounds   
S. 
No. 
Designed 
ligand 
Code 
Designed ligand Name No. of 
H-Bond 
Binding 
energy of 
best pose 
1 E1 (E)-1-(5-(4-(dimethylamino)phenyl)-3-(4-hydroxyphenyl)-4,5-dihydropyrazol-
1-yl)-3-phenylprop-2-en-1-one
 
None -4.64 
kcal/ mol 
2 E2 (E)-3-(4-chlorophenyl)-1-(5-(4-(dimethylamino)phenyl)-3-(4-
hydroxyphenyl)-4,5-dihydropyrazol-1-yl)prop-2-en-1-one
 
None -4.36 
kcal/ mol 
3 E3 (E)-1-(5-(4-(dimethylamino)phenyl)-3-(4-hydroxyphenyl)-4,5-dihydropyrazol-
1-yl)-3-(4-methoxyphenyl)prop-2-en-1-one
 
None -4.49 
kcal/ mol 
4 E4 (E)-1-(5-(4-(dimethylamino)phenyl)-3-(4-hydroxyphenyl)-
4,5-dihydropyrazol-1-yl)-3-(4-hydroxyphenyl)prop-2-en-1-
one
 
None -4.19 
kcal/ mol 
5 E5 (E)-3-(4-(dimethylamino)phenyl)-1-(5-(4-
(dimethylamino)phenyl)-3-(4-hydroxyphenyl)-4,5-
dihydropyrazol-1-yl)prop-2-en-1-one
 
02 -4.19 
kcal/ mol 
 
 
Figure 2: Binding pose of co-crystallized ligand 
Celecoxib 
 
Figure 3: Binding pose of designed compound E5.
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CONCLUSION: 
N-substituted-diaryl-pyrazoline analogues were 
designed and investigated for their insilico docking 
potential towards the COX-2 enzyme. The literature 
based rational approach was utilized for designing 
ligand molecule. The designed compounds were docked 
on the crystal structures of COX-2 (PDB entry 1CX2) 
obtained from RCSB Protein Data Bank. The 
Compound (E)-3-(4-(dimethylamino) phenyl)-1-(5-(4-
(dimethylamino) phenyl)-3-(4-hydroxyphenyl)-4,5 
dihydropyrazol-1-yl)prop-2-en-1-one (E5) was found to 
form hydrogen bond with Tyr-355 residue. This 
interaction suggested that designed analogues may be 
used as potent COX-2 inhibitor after further 
investigations. 
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